What is Immunai?
Immunai is an AI biotech company that decodes the human immune system at single-cell resolution, using multi-omic data, machine learning, and functional genomics to generate insights that guide immunotherapy development and oncology drug discovery. Its core platform, AMICA-OS, integrates one of the largest clinical immunology databases in the industry — built from harmonized single-cell data across internal experiments, academic partnerships, and public datasets — with foundation AI models trained specifically on immune biology. In April 2025, Immunai partnered with the Parker Institute for Cancer Immunotherapy to build what the organizations describe as the world's largest patient-centric single-cell dataset, drawing from 3,700 blood samples across 1,070 patients treated with immune checkpoint inhibitors. In January 2026, Bristol Myers Squibb signed a separate multi-year partnership focused on analyzing clinical immune data to clarify mechanisms of action and identify patient subgroups. In May 2026, Immunai expanded its oncology collaboration with AstraZeneca for the third time, with Immunai eligible to receive up to $37.5 million over 2026 and 2027 — signaling continued confidence from one of the world's largest biopharmaceutical companies in the platform's clinical utility. Immunai is not a general bioinformatics tool or a cloud-based sequencing service. Academic labs without access to matched clinical patient samples or organizations looking for a general-purpose single-cell analysis workflow will find the platform's strength — integrating patient sample data with the AMICA immune cell atlas — underutilized without the clinical data context that makes its machine learning models most predictive.
Immunai uses single-cell genomics and machine learning to map the human immune system through its AMICA-OS platform, accelerating biomarker discovery and immunotherapy development.
Immunai is widely used by professionals, developers, marketers, and creators to enhance their daily work and improve efficiency.
Key Features
Pros & Cons
Who Uses Immunai?
Immunai vs MyMap AI vs GPT for Sheets and Docs vs Pabbly Connect
Detailed side-by-side comparison of Immunai with MyMap AI, GPT for Sheets and Docs, Pabbly Connect — pricing, features, pros & cons, and expert verdict.
| Compare | ||||
|---|---|---|---|---|
Pricing |
unknown | Freemium | Freemium | Freemium |
Rating |
— | — | — | — |
Free Trial |
✕ | ✓ | ✓ | ✓ |
Key Features |
|
|
|
|
Pros |
The combination of CITE-seq multi-omic profiling at sin Single-cell resolution analysis reveals immune cell sub Integrating patient sample processing, AMICA database c | Converting a 30-page document or a complex topic descri The chat-based creation model means there is no interfa MyMap accepts source material from text, documents, URL | Running a language model prompt across an entire Google The freemium model provides access to base AI processin The add-on integrates as a standard Google Workspace si | Features a logical, step-by-step wizard that simplifies The lifetime deal provides massive long-term ROI, espec Backed by an active Facebook group of 21,000+ members a |
Cons |
Effective use of AMICA-OS requires expertise in single- Immunai's platform is optimized specifically for immune Enterprise partnership agreements, custom sequencing pr | The chat-based creation model is intuitive for simple d MyMap AI requires an active internet connection for all MyMap's AI-driven layout produces diagrams that are str | While the formula syntax is straightforward, writing ef GPT-4 Turbo and Claude 3 model calls generate token-bas GPT for Sheets and Docs operates exclusively within Goo | While no-code, mastering the logic of deep routers and While it covers 2,000+ apps, some niche enterprise trig Workflow reliability is tied to the API stability of th |
Best For |
Biopharmaceutical Companies | Students & Researchers | Content Creators | Small to Medium-Sized Businesses |
Verdict |
For biopharmaceutical organizations running immuno-oncology … | MyMap AI is the most accessible entry point for AI-generated… | For e-commerce managers, data analysts, and content teams wh… | Pabbly Connect is the 'utility player' of the automation wor… |
Try It |
Visit Immunai ↗ | Visit MyMap AI ↗ | Visit GPT for Sheets and Docs ↗ | Visit Pabbly Connect ↗ |
Immunai vs MyMap AI vs GPT for Sheets and Docs vs Pabbly Connect — Which is Better in 2026?
Choosing between Immunai, MyMap AI, GPT for Sheets and Docs, Pabbly Connect can be difficult. We compared these tools side-by-side on pricing, features, ease of use, and real user feedback.
Immunai vs MyMap AI
Immunai — Immunai is an AI Tool that applies single-cell genomics and foundation AI models to the specific challenge of immunotherapy development, using its AMICA-OS plat
MyMap AI — MyMap AI is an AI Tool that generates diagrams and mind maps from conversational input, uploaded files, URLs, and live web search results. Its chat-native desig
- Immunai: Best for Biopharmaceutical Companies, Academic Research Institutions, Drug Developers and Immunologists, Heal
- MyMap AI: Best for Students & Researchers, Professionals, Content Creators, Educators, Uncommon Use Cases
Immunai vs GPT for Sheets and Docs
Immunai — Immunai is an AI Tool that applies single-cell genomics and foundation AI models to the specific challenge of immunotherapy development, using its AMICA-OS plat
GPT for Sheets and Docs — GPT for Sheets and Docs is an AI Tool that brings multiple AI language models into Google Sheets and Docs through a simple add-on installation, enabling bulk te
- Immunai: Best for Biopharmaceutical Companies, Academic Research Institutions, Drug Developers and Immunologists, Heal
- GPT for Sheets and Docs: Best for Content Creators, Data Analysts, E-commerce Managers, Marketers, Uncommon Use Cases
Immunai vs Pabbly Connect
Immunai — Immunai is an AI Tool that applies single-cell genomics and foundation AI models to the specific challenge of immunotherapy development, using its AMICA-OS plat
Pabbly Connect — Pabbly Connect is a high-value automation engine that disrupts the market with its 'pay-once' lifetime model. By offering 2,000+ integrations and a generous pol
- Immunai: Best for Biopharmaceutical Companies, Academic Research Institutions, Drug Developers and Immunologists, Heal
- Pabbly Connect: Best for Small to Medium-Sized Businesses, E-commerce Platforms, Marketing Agencies, Freelancers, Uncommon Us
Final Verdict
For biopharmaceutical organizations running immuno-oncology programs with clinical patient samples sitting in biobanks, Immunai converts that underutilized asset into mechanistic immune insights that inform target selection, dose optimization, and patient stratification — capabilities that manual single-cell analysis workflows cannot deliver at the same speed or scale. Access is limited to institutional partnerships rather than self-service deployment.
FAQs
4 questionsExpert Verdict
Summary
Immunai is an AI Tool that applies single-cell genomics and foundation AI models to the specific challenge of immunotherapy development, using its AMICA-OS platform to turn raw clinical sample data into mechanistic insights about immune response, patient stratification, and drug target identification. Its 170-person team and nearly $270 million raised position it as one of the better-capitalized AI immunology platforms, with active multi-year partnerships at AstraZeneca and Bristol Myers Squibb demonstrating real-world adoption at pharmaceutical scale.
It is suitable for beginners as well as professionals who want to streamline their workflow and save time using advanced AI capabilities.
User Reviews
0 reviewsAlternatives to Immunai
6 tools
